Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | PRKCH | P24723 | 4/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.37 |
| ▸ | IL1B | P01584 | 6/20 | 0.37 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24379612 | 0.89 | NLRP3 (0.39) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL24379593 | 0.89 | NLRP3 (0.39) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL30770615 | 0.88 | KDR (0.39) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL27157422 | 0.88 | KDR (0.39) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL24379625 | 0.88 | NLRP3 (0.38) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL27157384 | 0.87 | IL1B (0.34) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL30697227 | 0.86 | NLRP3 (0.37) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL30770726 | 0.85 | KDR (0.40) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL30770679 | 0.85 | IL1B (0.41) | NLRP3KDRPRKCHPRKCEPRKCQ | |
| SCHEMBL30181277 | 0.85 | IL1B (0.46) | NLRP3KDRIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363406-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2024-05-08 | — | — | EP | claimed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | claimed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | claimed |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4320102-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275366-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022216971-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDR 4672/4885PRKCH 1152/4885 |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDR 4672/4885PRKCH 1152/4885 |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KDR 4384/4885PRKCH 3238/4885 |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | NLRP3 1/4885KDR 4505/4885PRKCH 1745/4885 |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDR 4372/4885PRKCH 3136/4885 |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | NLRP3 1/4885KDR 4505/4885PRKCH 1745/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KDR 4384/4885PRKCH 3238/4885 |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDR 4672/4885PRKCH 1152/4885 |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDR 4672/4885PRKCH 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.